| Literature DB >> 25635252 |
Yalda Zolghadri1, Mehdi Fazeli1, Marzieh Kooshki1, Tahoora Shomali1, Negar Karimaghayee1, Maryam Dehghani1.
Abstract
Interleukin-1β (IL-1β) has a role in β- cell destruction in autoimmune diabetes by stimulating the expression of inducible nitric oxide synthase (iNOS) that generates the free radical nitric oxide. We aimed to investigate the effect of Achillea millefolium L, as a traditional hypoglycemic agent, on IL-1β and iNOS gene expression of pancreatic tissue in the STZ- induced diabetic rats. Forty adult male Wistar rats were randomly divided into four groups: 1. diabetic control; 2. diabetic rats treated with Achillea millefolium L. extract; 3. normal rats received only extract and 4. negative control (n= 10 each). Diabetes was induced by single i.p. injection of 45 mg/ kg streptozotocin (STZ). Rats in groups 2 and 3 were treated with i.p. injection of Achillea millefolium L. extract (100 mg/ kg/ day) for 14 days. Body weight, serum glucose and insulin levels were assayed at baseline and on days 3, 7, 10 and 14 of the experiment. Finally, the quantity of pancreatic IL-1β and iNOS mRNA was determined by real- time PCR. The mRNA expression level of IL-1β and iNOS genes, was significantly (p<0.001) increased in diabetic rats of group 1. Treatment with Achillea millefolium L. caused a significant (p<0.01) reduction in both IL-1β and iNOS genes expression. Moreover, rats in group 2 had higher insulin level associated with lower glucose level and higher body weight compared to control diabetic group. It seems that beneficial effect of Achillea millefolium L. on STZ- induced diabetes is at least partly due to amelioration of IL-1β and iNOS gene over expression which can have a β-cell protective effect.Entities:
Keywords: Achillea millefolium L.; IL-1β; diabetes; gene expression; iNOS
Year: 2014 PMID: 25635252 PMCID: PMC4293613
Source DB: PubMed Journal: Int J Mol Cell Med ISSN: 2251-9637
Body weight (g), serum glucose (mg/dl) and insulin level (µU/ml) (mean±SEM) of rats in different sampling times (n=10 in each group).
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
| ||
| 0 | Body weight (g) | 217 ± 3.67 | 221 ± 4.82 | 218 ± 5.40 | 216 ± 4.23 |
| Blood glucose (mg/dl) | 97.33 ± 3.19 | 100.83 ± 4.59 | 97.67 ± 7.87 | 104.67 ± 4.42 | |
| Serum insulin (µU/ml) | 17.86 ± 1.06 | 16.32 ± 0.76 | 18.24 ± 0.89 | 17.65 ± 1.33 | |
| 3 | Body weight (g) | 214 ± 4.21 | 212 ± 3.88 | 214 ± 5.12 | 221 ± 3.95 |
| Blood glucose (mg/dl) | 332.83 ± 18.72a | 345.00 ± 14.70a | 101.50 ± 3.53b | 103.00 ± 6.51b | |
| Serum insulin (µU/ml) | 13.42 ± 0.87a | 14.38 ± 0.69a | 16.12 ± 1.04b | 17.02 ± 0.96b | |
| 7 | Body weight (g) | 202 ± 4.96a | 195 ± 4.22a | 219 ± 5.01b | 213 ± 3.89b |
| Blood glucose (mg/dl) | 380.67 ± 13.59a | 370.83 ± 9.60a | 109.33 ± 7.30b | 110.33 ± 7.55b | |
| Serum insulin (µU/ml) | 12.09 ± 0.66a | 12.31 ± 0.33a | 15.66 ± 1.13b | 18.12 ± 1.05b | |
| 10 | Body weight (g) | 196 ± 4.21a | 204 ± 3.97a | 218 ± 4.32b | 211 ± 5.23b |
| Blood glucose (mg/dl) | 392.00 ± 11.78a | 304.17 ± 9.12b | 102.67 ± 6.09c | 105.17 ± 4.04c | |
| Serum insulin (µU/ml) | 11.76 ± 0.47a | 14.89 ± 0.95b | 15.84 ± 0.90b | 16.21 ± 1.18b | |
| 14 | Body weight (g) | 188 ± 4.71a | 212 ± 3.27b | 220 ± 4.03b | 217 ± 3.77b |
| Blood glucose (mg/dl) | 403.50 ± 6.99a | 187.17 ± 12.02b | 107.17 ± 4.39b | 107.50 ± 6.29b | |
| Serum insulin (µU/ml) | 11.50 ± 0.27a | 15.72 ± 0.56b | 14.92 ± 1.00b | 15.96 ± 0.92b | |
Different superscript small lettersis used to show significant differences in the same row (p<0.05).
Fig. 2Relative difference (mean ± SD) in iNOS expression in pancreatic tissues of rats in different groups. Different letters are used to demonstrate significant differences (p< 0.05). The level of iNOS mRNA expression was estimated by quantitative real-time RT-PCR and normalized to the expression level of GAPDH gene
Fig. 1Relative difference (mean ± SD) in IL-1β expression in pancreatic tissues of rats in different groups. Different letters are used to demonstrate significant differences(p< 0.05). The IL-1β mRNA expression level was estimated using quantitative real-time RT-PCR and expressed relative to the expression level of GAPDH gene